NASDAQ:NVCR NovoCure - NVCR News Today Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding NovoCure Limited Please log in to your account or sign up in order to add this asset to your watchlist. $57.17 +0.36 (+0.63%) (As of 03/24/2023 12:00 AM ET) Add Compare Share Share Today's Range$56.06▼$57.6450-Day Range$56.44▼$95.0952-Week Range$56.06▼$120.03Volume561,258 shsAverage Volume1.09 million shsMarket Capitalization$6.03 billionP/E RatioN/ADividend YieldN/APrice Target$87.33 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Get NovoCure News Delivered to You Automatically Sign up to receive the latest news and ratings for NVCR and its competitors with MarketBeat's FREE daily newsletter. Email Address NVCR Media Mentions By Week NVCR Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NVCR News Sentiment▼0.180.52▲Average Medical News Sentiment NVCR News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NVCR Articles This Week▼53▲NVCR Articles Average Week All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineArmstrong Advisory Group Inc. Purchases New Shares in NovoCure Limited (NASDAQ:NVCR)marketbeat.com - March 24 at 6:23 AMNovoCure Limited (NASDAQ:NVCR) Shares Sold by Peregrine Capital Management LLCmarketbeat.com - March 20 at 5:47 AMJPMorgan Chase & Co. Reaffirms "Underweight" Rating for NovoCure (NASDAQ:NVCR)americanbankingnews.com - March 20 at 3:36 AMInstitutional investors may adopt severe steps after NovoCure Limited's (NASDAQ:NVCR) latest 7.3% drop adds to a year lossesfinance.yahoo.com - March 16 at 3:41 PMNovocure Announces Reimbursement of Optune® for the Treatment of Newly Diagnosed Glioblastoma in Francefinance.yahoo.com - March 1 at 12:07 PMNovoCure Full Year 2022 Earnings: US$0.88 loss per share (vs US$0.56 loss in FY 2021)finance.yahoo.com - February 24 at 7:39 AMNovoCure Full Year 2022 Earnings: US$0.88 loss per share (vs US$0.56 loss in FY 2021)finance.yahoo.com - February 24 at 7:39 AMWhy NovoCure Stock Is Falling Todayfinance.yahoo.com - February 23 at 4:37 PMShould You Investigate NovoCure Limited (NASDAQ:NVCR) At US$87.50?finance.yahoo.com - February 10 at 5:58 AMNovocure Round-Trips Its Recent Breakout After Announcing A Series Of C-Suite Changesfinance.yahoo.com - January 19 at 3:10 PMNovocure Has Fallen More Than 20% Over Seven Days — Why It Fell From Gracefinance.yahoo.com - January 17 at 1:29 PMWhy Novocure Stock Is Flying Highfinance.yahoo.com - January 6 at 8:16 AMNovocure Skyrockets 69% After Pulling Off A Once-In-Six-Years Featfinance.yahoo.com - January 5 at 7:54 PMWhy Novocure Stock Is Skyrocketing Todayfinance.yahoo.com - January 5 at 2:49 PMNovocure to Participate in 41st Annual J.P. Morgan Healthcare Conferencefinance.yahoo.com - December 27 at 8:32 AMIs NovoCure Limited (NASDAQ:NVCR) Worth US$74.7 Based On Its Intrinsic Value?finance.yahoo.com - November 30 at 11:49 AMNovocure Stock: Bull vs. Bearfinance.yahoo.com - November 26 at 6:12 AMNovocure Opens Office in Montreal to Expand and Support Growing Business in Canadafinance.yahoo.com - November 15 at 9:39 AMNovocure Secures CE Mark for New Arrayfinance.yahoo.com - November 11 at 1:02 PM2 Potentially Explosive Stocks to Buy in Novemberfinance.yahoo.com - November 8 at 1:50 PMNovoCure's Return On Capital Employed Insightsmsn.com - November 4 at 1:37 PMNovoCure (NVCR) Reports Q3 Loss, Lags Revenue Estimatesfinance.yahoo.com - October 27 at 6:06 PMNovocure (NVCR) Q3 2022 Earnings Call Transcriptfinance.yahoo.com - October 27 at 6:06 PMNovoCure downgraded at Piper Sandler despite positive Phase 3 readout aheadseekingalpha.com - October 25 at 1:10 PMWhy Novocure Stock Is Sinking Todayfinance.yahoo.com - October 24 at 9:12 PMNovoCure (NASDAQ:NVCR) shareholders have earned a 30% CAGR over the last five yearsfinance.yahoo.com - October 23 at 7:43 PM3 Unstoppable Stocks You Can Buy Now for Less Than $100 - Nasdaqnasdaq.com - October 13 at 10:57 AMThe Clock Is Ticking to Buy This Game-Changing Stock at a Discount - Nasdaqnasdaq.com - October 6 at 10:17 AMThe Clock Is Ticking to Buy This Game-Changing Stock at a Discountfinance.yahoo.com - October 6 at 10:17 AMNovocure to Report Third Quarter 2022 Financial Resultsfinance.yahoo.com - October 3 at 8:15 AMNovoCure: See Past Market Myopia And Buy The Dip (NASDAQ:NVCR) - Seeking Alphaseekingalpha.com - September 27 at 8:40 PMNVCR Makes Notable Cross Below Critical Moving Average - Nasdaqnasdaq.com - September 23 at 9:45 AMNovoCure Whale Trades For September 21 - NovoCure (NASDAQ:NVCR) - Benzingabenzinga.com - September 21 at 6:57 PMNovocure Announces Creation of U.S. CNS Cancers Franchise Intended to Renew Focus on Growth in Glioblastoma Business - Business Wirebusinesswire.com - September 21 at 10:03 AMNovocure Announces Creation of U.S. CNS Cancers Franchise Intended to Renew Focus on Growth in Glioblastoma Businessfinance.yahoo.com - September 21 at 10:03 AMNovoCure Appears Poised for an Upside Breakout - RealMoneyrealmoney.thestreet.com - September 14 at 11:01 PMNovocure Earns Relative Strength Rating Upgrade - Investor's Business Dailyinvestors.com - September 12 at 10:54 AMUPDATE 1-Ivory Coast sells 2023/24 cocoa contracts with positive origin differential - Yahoo Financefinance.yahoo.com - September 12 at 10:54 AMAfter losing 33% in the past year, NovoCure Limited (NASDAQ:NVCR) institutional owners must be relieved by the recent gainfinance.yahoo.com - September 12 at 10:54 AMNovoCure Appears Poised for an Upside Breakoutfinance.yahoo.com - September 12 at 10:54 AMAlpha Tau Appoints Industry Veteran Peter Melnyk as Chief Commercial Officer - Yahoo Financefinance.yahoo.com - September 1 at 10:36 PMAlpha Tau Appoints Industry Veteran Peter Melnyk as Chief Commercial Officer - StreetInsider.comstreetinsider.com - September 1 at 5:34 PMNovocure to Participate in Upcoming Investor Conferences - Yahoo Financefinance.yahoo.com - September 1 at 3:30 AMNovocure to Participate in Upcoming Investor Conferences - Business Wirebusinesswire.com - August 31 at 12:02 PMNovocure to Participate in Upcoming Investor Conferencesfinance.yahoo.com - August 31 at 12:02 PMWhy I Own Novocure Stock (NVCR) - The Motley Foolfool.com - August 22 at 11:45 AMWhy I Own Novocure Stock (NVCR)finance.yahoo.com - August 22 at 11:45 AMRich Insights Into The Robust Metastatic Melanoma Clinical Trials Pipeline Analysis Featuring 75+ Companies DelveInsight - GlobeNewswireglobenewswire.com - August 18 at 2:50 PMNovocure Hosts U.S. Sen. Maggie Hassan at Company's Portsmouth Facility - Business Wirebusinesswire.com - August 10 at 1:06 PMThe Chief Medical Officer of NovoCure Limited (NASDAQ:NVCR), Ely Benaim, Just Sold 89% Of Their Holdingnasdaq.com - August 8 at 1:44 PMNovoCure Earnings Perspective: Return On Capital Employedmsn.com - August 4 at 1:34 PM5 Top Stocks for August - The Motley Foolfool.com - August 1 at 4:47 AM Get NovoCure News Delivered to You Automatically Sign up to receive the latest news and ratings for NVCR and its competitors with MarketBeat's FREE daily newsletter. Email Address This page (NASDAQ:NVCR) was last updated on 3/25/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.